In addition, it has been shown that combined inhibition of the Hh and PI3K/AKT pathways has synergistic anti-leukemia effects in AML and in chronic lymphocytic leukemia21, 22, 23. This evidence concerns the gene AKT1 and acute myeloid leukemia.